2023-506697-12-00已完成1 期
MK-8507 Extended Multiple Dose Study
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2023年10月2日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Marian Iwamoto
Scientific
Merck Sharp & Dohme LLC
研究点 (1)
Loading locations...
相似试验
已完成
不适用
SK-5307 P I multiple-dose studyjRCT2071220064Sanwa Kagaku Kenkyusho Co.,Ltd.12
招募中
1 期
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients with Mild Cognitive Impairment due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease (I8G-MC-LMDD)Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's DiseaseJPRN-jRCT2080223501Eli Lilly Japan K.K.
招募中
1 期
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients with Mild Cognitive Impairment due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease (I8G-MC-LMDD)jRCT2080223501Eli Lilly Japan K.K.
进行中（未招募）
不适用
A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-interleukin 6 (IL-6) Monoclonal Antibody, in Subjects with Solid TumorsEUCTR2008-005180-33-GBJanssen Biologics B.V.90
进行中（未招募）
1 期
A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-interleukin 6 (IL-6) Monoclonal Antibody, in Subjects with Solid TumorsMalignant solid tumorsMedDRA version: 9.1Level: LLTClassification code 10065147Term: Malignant solid tumorEUCTR2008-005180-33-BEJanssen Biologics B.V.90